Log in to search using one of your social media accounts:

 

Nutra Labs Inc. Issues Voluntary Nationwide Recall of Dietary Supplements Bull and Chao Jimengnan Tablets Due to Undeclared Active Pharmaceutical Ingredients

Nutra Labs Inc. is voluntarily recalling lots sold by their firm of the male enhancement supplements Bull 1800 mg Capsules with the production date of 05/08/2016, and Chao Jimengnan 150 mg Tablets with Lot # 20151018 to the consumer level. FDA analysis found the products to be tainted with sildenafil, 0.026mg/capsule for Bull, and 70.46mg/tablet for Chao Jimengnan respectively. Sildenafil is the active pharmaceutical ingredient in an FDA approved product used for erectile dysfunction, making Bull capsules and Chao Jimengnan tablets unapproved new drugs.
Source: Food and Drug Administration - Category: Food Science Source Type: news

Related Links:

This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - Category: Endocrinology Authors: Tags: Letter Source Type: research
AbstractPhosphodiesterase type 5 inhibitors (PDE5Is) are the drug of choice for medical management of erectile dysfunction (ED). On-demand PDE5Is have an overall efficacy of 60 –70% for ED; 30–35% of patients fail to respond to a PDE5I, and 30–50% of non-responders can be salvaged with detailed counseling on proper use and physician follow-up to ensure that the patient has been prescribed an appropriate and full PDE5I clinical trial. True non-responders may be offere d intracavernosal injections of erectogenic drugs, intraurethral alprostadil, or surgical insertion of a penile prosthesis. Such options are...
Source: Drugs and Aging - Category: Geriatrics Source Type: research
F. Lugoboni, L. Zamboni, A. Federico and S. Tamburin; Gruppo InterSERT di Collaborazione Scientifica
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Urological Survey Source Type: research
(Reuters) - The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc's Vitaros, a cream to treat erectile dysfunction, for the second time in a decade, sending the company's shares down more than 70 percent before the opening bell.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
(Reuters) - The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc's Vitaros, a cream treatment for erectile dysfunction, for the second time in a decade.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Publication date: Available online 15 February 2018 Source:Sexologies Author(s): M.H. Colson, B. Cuzin, A. Faix, L. Grellet, E. Huyghes Depuis la dernière actualisation des recommandations pour la prise en charge de la dysfonction érectile (DE) par le praticien, les études épidémiologiques ont confirmé les premiers chiffres donnés par les grandes études internationales dès la fin des années 1990. D’autres données se sont précisées et nous permettent aujourd’hui de mieux comprendre le profil épidémiologique ...
Source: Sexologies - Category: Sexual Medicine Source Type: research
This report also highlights the fact that the percentage of patients with dysphoria, which is much higher among the Klinefelter syndromes in the literature, might be due to the lack of testosterone treatment. This atypical and uncommon observation could be sought at larger scales in patients with fluctuating dysphoria. Finally and more broadly, it also recalls the importance of researching the total testosterone levels of patients suffering from dysphoria, which do not suffer from a psychiatric pathology.
Source: Sexologies - Category: Sexual Medicine Source Type: research
Publication date: Available online 15 February 2018 Source:Sexologies Author(s): M.H. Colson, B. Cuzin, A. Faix, L. Grellet, E. Huyghes Since the most recent update to guidelines for the management of erectile dysfunction (ED) by practitioners, epidemiological studies have confirmed the main figures emerging from the large international studies done in the late 1990s. Other data have emerged, and we now have a better understanding of the epidemiological profile of ED. Its prevalence for all age groups appears to be between 12.9% (11.5–14.3) in southern Europe and 20.6% (18.8–22.4) in English-speaking countries...
Source: Sexologies - Category: Sexual Medicine Source Type: research
ObjectiveTo evaluate the cancer control outcomes and long‐term treatment‐related morbidity of brachytherapy as well as combination brachytherapy and external beam radiation therapy (EBRT) in patients with intermediate‐risk prostate cancer. Materials and MethodsA retrospective review was conducted in a prospectively collected database of patients with intermediate‐risk prostate cancer who were treated either with brachytherapy or brachytherapy and EBRT, with or without androgen deprivation therapy (ADT), in the period 1990–2014. Urinary and erectile dysfunction symptoms were measured using the International Pr...
Source: BJU International - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research
Even though several scholars have conducted study in different part of the world on erectile dysfunction in patients diagnosed with diabetes mellitus, it ’s magnitude vary among their finding with the range bet...
Source: BMC Research Notes - Category: Research Authors: Tags: Research note Source Type: research
More News: Complementary Medicine | Diets | Erectile Dysfunction | Food and Drug Administration (FDA) | Food Science | Nutrition | Viagra